ÂÜÀòÂÒÂ×

Caroline has extensive experience in drug discovery and early clinical development. She has been instrumental in the development of Redx’s oncology pipeline, including progressing Redx’s lead oncology asset, RXC004, a potential best-in-class, orally bioavailable porcupine inhibitor into two Phase 1 studies and signing a research collaboration with Jazz Pharmaceuticals for two targeted cancer therapies.